<code id='FD64BB15DA'></code><style id='FD64BB15DA'></style>
    • <acronym id='FD64BB15DA'></acronym>
      <center id='FD64BB15DA'><center id='FD64BB15DA'><tfoot id='FD64BB15DA'></tfoot></center><abbr id='FD64BB15DA'><dir id='FD64BB15DA'><tfoot id='FD64BB15DA'></tfoot><noframes id='FD64BB15DA'>

    • <optgroup id='FD64BB15DA'><strike id='FD64BB15DA'><sup id='FD64BB15DA'></sup></strike><code id='FD64BB15DA'></code></optgroup>
        1. <b id='FD64BB15DA'><label id='FD64BB15DA'><select id='FD64BB15DA'><dt id='FD64BB15DA'><span id='FD64BB15DA'></span></dt></select></label></b><u id='FD64BB15DA'></u>
          <i id='FD64BB15DA'><strike id='FD64BB15DA'><tt id='FD64BB15DA'><pre id='FD64BB15DA'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:22932

          Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

          advertisement

          For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          Wikipedia

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion
          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

          YichuanCao/SipaUSAGileadSciencessaidMondayitwillacquireCymaBayTherapeuticsfor$4.3billion,addinganewt

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          Gilead might be held responsible for not developing a drug

          JustinSullivan/GettyImagesTheassaultonthedevelopmentofnewlifesavingtherapiescontinuesapace.Recently,